Notable correlation between serum epidermal growth factor values and inflammatory status in patients with COVID‐19.

Introduction: Despite its crucial role in Epidermal Growth Factor Receptor (EGFR) activation, and the resulting impact on the health‐disease process, epidermal growth factor (EGF) is an underexplored molecule in relation to how its serum concentrations relate to other analytes and clinical variables in pathological contexts. Objective: To clarify the possible correlation between EGF and clinical and analytical variables in the context of COVID‐19. Methods: Cross‐sectional observational and analytical study, in patients with virological and clinical diagnosis of COVID‐19, selected by simple random sampling, admitted between August and September 2021. UMELISA‐EGF commercial kits were used. Results: Differences in overall EGF values were observed between groups (566.04 vs. 910.53 pg/ml, p =.0430). In COVID‐19 patients, no notable correlations were observed for neutrophil, platelet, triglyceride or liver enzyme values (p >.05). Significant correlations were observed with the neutrophil‐lymphocyte indicator (r = 0.4711, p =.0128) as well as with the platelet‐lymphocyte index (r = 0.4553, p =.0155). Statistical results of multivariate regression analysis suggest NLR (β =.2232, p =.0353) and PLR (β =.2117, p =.0411) are predictors of inflammation in patients with COVID‐19. Conclusions: Serum EGF concentrations in COVID‐19 correlate positively with prognostic inflammatory markers of severity and could presumably act as an independent risk factor for the development of inflammation in response to new severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). [ABSTRACT FROM AUTHOR]